“Cell Adhesion Molecules in Plasticity and Metastasis”
Smart JA, Oleksak JE, Hartsough EJ
Mol. Can. Res. 2020 Oct 1
“Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis”
Erkes DA, Cai W, Sanchez IM, Purwin TJ, Rogers C, Field CO, Berger AC, Hartsough EJ, Rodeck U, Alnemri ES, Aplin AE
Cancer Discov. 2020 Jan 24; online ahead of print
“The next generation BET inhibitor PLX51107 delays melanoma growth by altering the tumor immune microenvironment”
Erkes DA, Capparelli C, Heilman SA, Chervoneva I, Berger AC, Rosenbaum SR, Hartsough EJ, Villanueva J, Aplin AE
Pigment Cell Melanoma Res. 2019 Sep;32(5):687-696
"CADM1 is a TWIST1-regulated suppressor of melanoma invasion and survival"
Hartsough EJ, Weiss MB, Heilman SA, Purwin TJ, Kugel CH 3rd, Rosenbaum SR, Erkes DA, Tiago M, HooKim K, Chervoneva I, Aplin AE
Cell. Death Dis.;10(4):281, Mar 25, 2019
"BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association"
Vido MJ, Le K, Hartsough EJ, Aplin AE
Cell Rep.; 25(6):1501-1510, Nov 6, 2018
"Mutant BRAF selective inhibitor with paradox breaking properties in human
melanomas ex vivo and in vivo"
Hartsough EJ, Kugel CH 3rd, Berger AC, Basile KJ, Purwin T, Goldberg A, Davies MA, Schiewer
MJ, Bollag G, Aplin AE
Mol. Cancer Ther.;12(1):84-95, Jan 2018
"αC IN, αC OUT-that’s what it’s all about"
Hartsough EJ, Vido MJ
Pigment Cell Melanoma Res.;30(2):177-178, Mar 2017
"Of mice and melanoma: PDX system for modeling personalized
medicine"
Hartsough EJ, Aplin AE
Clin Cancer Res.;22(7):1550-2, Apr 1, 2016
"RNF121 inhibits angiogenic growth factor signaling by restricting cell surface expression of VEGFR-2"
Maghsoudlou A, Meyer RD, Arafa E, Rezazadeh K, Bondzie PA, Pudney J, Hartsough E, Chitalia
V, Rahimi N
Traffic;17(3):289-300, Mar 2016
"TMIGD1 is a novel adhesion molecule that protects epithelial cells from oxidative cell injury"
Arafa E, Bondzie PA, Rezazadeh K, Meyer RD, Hartsough E, Henderson JM, Schwartz
JH, Chitalia V, Rahimi N
Am J Pathol.;185(10):2757-67, Oct 2015
"Hypoxia-induced expression of phosducin-like 3
regulates expression of VEGFR-2 and promotes angiogenesis"
Srinivasan S, Chitalia V, Meyer RD, Hartsough E, Mehta M, Harrold I, Anderson N, Feng H,
Smith LE, Jiang Y, Costello CE, Rahimi N
Angiogenesis;18(4):449-
62, Oct 2015
"Function-blocking ERBB3
antibody inhibits the adaptive response to RAF inhibitor"
Kugel CH 3rd, Hartsough EJ, Davies MA, Setiady YY, Aplin AE
Cancer Res.;74(15):4122-32, Aug 1, 2014
"Beneficial effects of RAF inhibitor in mutant BRAF splice
variant-expressing melanoma"
Hartsough EJ, Basile KJ, Aplin AE
Mol Cancer Res.;12(5):795-802, May 2014
"Inhibition of mutant BRAF splice variant signaling by
next-generation, selective RAF inhibitors"
Basile KJ, Le K, Hartsough EJ, Aplin AE
Pigment Cell Melanoma Res.;27(3):479-84, May 2014
"Resistance to RAF inhibitors revisited"
Hartsough E, Shao Y, Aplin AE
J Invest Dermatol.;134(2):319-25, Feb 2014
"Lysine methylation promotes VEGFR-2 activation and angiogenesis"
Hartsough EJ, Meyer RD, Chitalia V, Jiang Y, Marquez VE, Zhdanova IV, Weinberg J, Costello
CE, Rahimi N
Sci Signal.;6(304):ra104, Dec 3, 2013
"In vivo MAPK reporting
reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors"
Basile KJ, Abel EV, Dadpey N, Hartsough EJ, Fortina P, Aplin AE
Cancer Res.;73(23):7101-10, Dec 1, 2013
"A STATement on vemurafenib-resistant melanoma"
Hartsough EJ, Aplin AE
J Invest Dermatol.;133(8):1928-9,
Aug 2013
"Identification of IGPR-1 as a
novel adhesion molecule involved in angiogenesis"
Rahimi N, Rezazadeh K, Mahoney JE, Hartsough E, Meyer RD
Mol Biol Cell.;23(9):1646-56, May 2012